Trial Profile
Retrospective study of early lenvatinib dose reduction in thyroid cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2018
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2018 New trial record